Clinical Trials · NCT02146079

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
44
Start date
May 2014
Locations
1 site, Japan
Primary endpoint
Area under the plasma semaglutide concentration-time curve
View Semaglutide compound reference